Indaptus reports positive Phase 1 results for Decoy20; moves to multi-dose trial

Indaptus Therapeutics, Inc.

Second cohort of Phase 1 INDP-D101 trial showed broad immune response consistent with first cohort.
Independent Safety Review Committee recommended continuing to multiple doses of Decoy20.
Company has started screening patients for multi-dose safety and efficacy across multiple cancer types.
Animal models demonstrated Decoy20 safety in several multiple-dose schedules.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.